Venture capitalists invested more than $451 million in 14 different Maryland companies in the fourth quarter, tripling the amount raised in the third quarter. It was the state’s best quarter since the second quarter of 2006, when just over $406 million was raised.
This position is located in the Office of Technology Transitions and reports directly to the Director, Office of Technology Transitions. If selected for this position, you will manage the OTT staff, as the advisor to the Director, and provide continuity between administrations. The Deputy Director will be a senior level staff serving as a point of contact for entities like the Laboratory Operations (LOB), Laboratory Policy Council (LPC), and Secretary’s External Advisory Board (SEAB). The Deputy Director will manage the intra-agency tech Transfer Policy Board (TTPB). The Deputy Director will serves as an integral part of the Office of Technology Transitions, overseeing the day-today operations of the Office, continuously seeking efficiencies by providing oversight and coordination. The Deputy Director will develop and manage fit-for purpose oversight processed and procedures for technology transfer and reporting systems, including intellectual property, across the DOE enterprise. The Deputy Director will lead the development of annual OTT deliverables, working with appropriate DOE programmatic elements. The Deputy Director will lead OTT staff to ensure delivery of state of the art data management processes and solutions supporting effective technology transitions and outreach to the private sector. The Deputy Director will lead interactions needed with the Executive Office of the White House, the Office of Management and Budget (OMB), the General Services Administration (GSA), Congressional Committees and Subcommittees, State Officials, the non-profit sector, and other non-commercial entities to ensure DOE technology transitions polices and priorities are appropriately linked with related initiatives, and to improve existing, or develop new, processes and procedures for supporting technology transfer solutions.
The Obama administration has launched a ‘moonshot’ initiative to cure cancer that will involve increasing resources – both private and public – to fight cancer and break down walls between disciplines in the oncology arena. The effort will be led by vice president Joe Biden, who lost his son to brain cancer last year, President Obama announced during his final State of the Union speech. Biden worked with Congress last month to provide the US National Institutes of Health with its strongest budget in over a decade, Obama noted. ‘Let’s make America the country that cures cancer once and for all,’ he added.
Washington-area businesses raised more venture capital in the fourth quarter than they had in any quarter since 2001 — largely due to a few large deals.
The surge is not likely to be repeated soon given the recent stock market turmoil. Indeed, venture funding nationally declined during the period.
The TCM Industry Awards Celebration is the only awards ceremony that honors the best in Maryland’s technology and life science communities and is one of Maryland’s largest and most prestigious award ceremonies.
Awards go to those who develop the treatments, design the systems, and teach the children. It’s a celebration of great minds and the companies that believe in the future, and is attended by over 800 executives from the technology and life science industries, drawing a significant amount of local and national publicity.
What’s the difference between a relatively flat economy and a vibrant and diversified region with high job and economic growth? Working together. That was the pitch Thursday morning as economist Steve Fuller unveiled the findings after months of research for a project dubbed “ The Roadmap for the Washington Region’s Economic Future.”
You’ve heard of 3-D printers creating architectural models, airplane parts and even prosthetic limbs. But bones? Warren Grayson, an assistant professor of biomedical engineering at Johns Hopkins University, says it’s possible and not so far off in the future.
TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Kenneth Clark remembers the last time new investors moved into biotech. They came in the late 1980s.
They left in the early ’90s.
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an investment of CAD $40M from GE and FedDev Ontario. The centre is being established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. CCRM and GE will welcome partners from pharma, biotech and cell therapy companies to bring this initiative to life.
